The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures
Peyman Hadji(Philipps University of Marburg), John L. Stock(Eli Lilly (United States)), Kenneth G. Saag(University of Alabama at Birmingham), Mark Lakshmanan(Eli Lilly (United States)), Daniel N. Masica(Eli Lilly (United States)), Jahangir Alam(Eli Lilly (United States)), Christopher Recknor(Bone Health and Osteoporosis Foundation), Stuart L. Silverman(Cedars-Sinai Medical Center), John H. Krege(Eli Lilly (United States)), Bruce Mitlak(Radius Health (United States)), Fergus E. McKiernan(Marshfield Clinic), Russel Burge(Eli Lilly (United States)), Luis Augusto Tavares Russo, José Zanchetta(Universidad del Salvador)
Cited by 135
Related Papers
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.4k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
Generation and reproductive phenotypes of mice lacking estrogen receptor β
|Proceedings of the National Academy of Sciences|1998|1.7k
Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
|New England Journal of Medicine|1997|1.6k